CXCR1 Depletion in Ly6C
Summary
This mechanistic study identifies Ly6C+ cDC2 (mouse; human CD14+ cDC2) as CXCR1-high, pro-inflammatory dendritic cells that promote Th17 differentiation via MEK1/ERK/NF-κB-driven IL-6/IL-1β. DC-specific Cxcr1 depletion reduced Th17/Treg imbalance, attenuated LPS-induced ALI severity, and lowered mortality.
Key Findings
- Ly6C+ cDC2 (human CD14+ cDC2) highly express CXCR1 and are pro-inflammatory in ALI.
- Cxcr1 deficiency reduces IL-6/IL-1β production by Ly6C+ cDC2 and shifts naïve T cells toward Treg, lowering the Th17/Treg ratio.
- Adoptive transfer of Ly6C+ cDC2 worsens LPS-induced lung injury, while DC-specific Cxcr1 deletion reduces ALI severity and mortality via MEK1/ERK/NF-κB signaling.
Clinical Implications
Targeting CXCR1 or modulating cDC2-mediated Th17/Treg balance may attenuate inflammatory lung injury and guide biomarker development in ALI/ARDS.
Why It Matters
It uncovers a dendritic-cell CXCR1 axis that mechanistically links innate signaling to T-cell skewing and lung injury, nominating CXCR1 on cDC2 as a therapeutic target for ALI/ARDS.
Limitations
- Findings are primarily from LPS-induced ALI models, which may not recapitulate all ARDS etiologies
- No testing of pharmacologic CXCR1 inhibition in clinically relevant models
Future Directions
Evaluate pharmacologic CXCR1 blockade in diverse injury models and validate CXCR1+ cDC2 signatures and Th17/Treg biomarkers in patient cohorts.
Study Information
- Study Type
- Case series
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic mouse study with ex vivo human validation; no clinical outcomes.
- Study Design
- OTHER